<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343560</url>
  </required_header>
  <id_info>
    <org_study_id>18-009787</org_study_id>
    <nct_id>NCT04343560</nct_id>
  </id_info>
  <brief_title>MACS and Healthy Volunteers Bone Study</brief_title>
  <official_title>Effects of Abnormal Steroid Metabolome on Bone Strength and Quality, Bone Density, Bone Remodeling, and Body Composition in Patients With MACS and Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adrenal adenoma is detected in 5-7% of adults and demonstrates mild autonomous cortisol
      secretion (MACS, dexamethasone suppression test &gt;1.8 mcg/dl) in 50% of individuals with
      adenoma. Published reports suggest a 48%-52% 2-year incidence of new vertebral fractures in
      patients with MACS without any significant changes in bone density measurements. A
      disproportionate decrease in bone quality versus density or other factors such as sarcopenia
      potentially contribute to development of new vertebral fractures. Determining which specific
      abnormalities in the steroid metabolome affect bone density, quality and strength as well as
      bone remodeling markers and body composition will potentially serve as a diagnostic biomarker
      of clinical significance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, we will determine whether patients with MACS (versus healthy age and sex
      matched controls) demonstrate: 1) decreased bone strength and quality disproportionate to the
      decrease of bone density and 2) abnormalities in the steroid metabolome correlate with the
      degree of abnormalities in bone parameters. In a cross-sectional study of 75 patients with
      MACS and 75 age- and sex-matched healthy controls, we will determine the relationship of the
      steroid metabolome to measurements of bone density, quality and strength, bone turnover
      markers, as well as body composition. All patients will be interviewed in regards to their
      health, to include questions on bone health, frailty, cognition (NIH toolbox), and quality of
      life. We will measure 1) BMD (bone mineral density) at the lumbar spine, hip and radius and
      body composition using dual-energy X ray absorptiometry (DXA), 2) radial and tibial bone
      microstructure by high-resolution peripheral quantitative computed tomography (HR-pQCT), 4)
      bone turnover markers (osteocalcin, PINP, CTx, sclerostin). 5) Age reader measurement, 6)
      hand grip measurement, 7) 6 minute walk test. All patients will provide a 24 h urine for
      steroid metabolome analysis. For primary outcomes, we will determine if steroid metabolome
      profiling better predicts abnormal bone strength (as measured by trabecular bone
      volume/tissue volume [BV/TV] ratio).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BV/TV ratio</measure>
    <time_frame>0-24 months</time_frame>
    <description>measured by computed tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>steroid metabolome</measure>
    <time_frame>0-24 months</time_frame>
    <description>24h urine steroid profiling</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>MACS Syndrome</condition>
  <arm_group>
    <arm_group_label>patients with MACS</arm_group_label>
    <description>Patients with adrenal adenoma and dexamethasone suppression test &gt;1.8 mcg/dl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>no history of adrenal and pituitary disease, no exogenous steroids</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      24 hour urine collection in day and night containers. Serum blood to be analyzed for PTH,
      sclerostin, Ca, P, CTX, osteocalcin, PINP, Total and free cortisol.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MACS participants either male or female who are at least 18 years of age who fulfill the
        inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with MACS

          -  Age 18-no maximum

          -  exogenous steroids therapy within the last 5 years ( for more than 3 months ,
             prednisone equivalent &gt;7.5 mg daily)

          -  steroid hormone replacement therapy

          -  any drug therapy affecting bone metabolism

          -  recent fracture

        Exclusion Criteria:

          -  exogenous steroids therapy within the last 5 years ( for more than 3 months ,
             prednisone equivalent &gt;7.5 mg daily)

          -  steroid hormone replacement therapy ( for adrenal insufficiency, hypogonadism,
             menopause)

          -  therapy for osteoporosis

          -  any drug therapy affecting bone metabolism

          -  comorbidities affecting steroid metabolome or bone metabolism

          -  recent fracture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Bancos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melinda Thomas</last_name>
    <phone>507-293-6628</phone>
    <email>thomas.melinda@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Thomas</last_name>
      <phone>507-293-6628</phone>
      <email>thomas.melinda@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Irina Bancos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Irina Bancos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

